🇺🇸 Live Combined Bifidobacterium and Lactobacillus in United States

18 US adverse-event reports

Marketing authorisation

FDA

  • Status: approved

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

Most-reported reactions

  1. Drug-Induced Liver Injury — 3 reports (16.67%)
  2. Hepatic Function Abnormal — 2 reports (11.11%)
  3. Hyperglycaemia — 2 reports (11.11%)
  4. Hyperphosphataemia — 2 reports (11.11%)
  5. Hypokalaemia — 2 reports (11.11%)
  6. Lymphocyte Count Decreased — 2 reports (11.11%)
  7. Pneumonia — 2 reports (11.11%)
  8. Abdominal Discomfort — 1 report (5.56%)
  9. Acute Kidney Injury — 1 report (5.56%)
  10. Acute Left Ventricular Failure — 1 report (5.56%)

Source database →

Live Combined Bifidobacterium and Lactobacillus in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Frequently asked questions

Is Live Combined Bifidobacterium and Lactobacillus approved in United States?

Yes. FDA has authorised it.

Who is the marketing authorisation holder for Live Combined Bifidobacterium and Lactobacillus in United States?

First Affiliated Hospital Xi'an Jiaotong University is the originator. The local marketing authorisation holder may differ — check the official source linked above.